They met, fell in love, started a gene therapy company. Now they've raised $104 million to target diseases that were unreachable.

The company's first target is Dravet syndrome, a rare genetic disorder marked by dozens of seizures a day.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 26, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news